Summit Therapeutics touts a rare triumph over Keytruda in lung cancer from a China-only Phase 3 study

Hours before America’s biggest cancer conference starts in Chicago, a small biotech may have stolen the show, touting late-stage results in a Thursday afternoon press …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SphingoTec Closes €5M Series C to Accelerate Market Development and Financial Growth with Innovative Biomarkers – Biotech Investments

Issuer: SphingoTec GmbH / Key word(s): Financing/Investment 08.08.2024 / 10:00 CET/CEST The issuer is solely responsible for the content of this announcement. SphingoTec GmbH has

August 9, 2024

Ayble and Commure Integrate to Tackle Chronic GI Care Crisis

What You Should Know: – Ayble Health, a digital health platform for patients with chronic gastrointestinal (GI) conditions, and Commure Engage, an AI-powered care coordination

December 22, 2023

The roles and plausible mechanisms of pyroptosis in renal inflammation and fibrosis

Researchers summarize available data on pyroptosis in the context of renal fibrosis, as well as its prevention and treatment.

August 1, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.